Table 2 Serum apolipoprotein A1 (APOA1) and apolipoprotein B (APOB) levels in relation to clinical and pathological characteristics of tumors

From: Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer

 

APOA1 (g/L), median (IQR)

P value

APOB (g/L), median (IQR)

P value

APOB/APOA1 ratio, median (IQR)

P value

Gender

Male (n = 77)

1.283 (1.201–1.390)

0.034

0.747 (0.652–0.884)

0.908

0.585 (0.502–0.680)

0.292

Female (n = 67)

1.346 (1.247–1.451)

0.753 (0.651–0.869)

0.562 (0.497–0.657)

Age

< 65 years (n = 58)

1.285 (1.230–1.435)

0.651

0.781 (0.675–0.928)

0.035

0.599 (0.509–0.699)

0.063

≥ 65 years (n = 86)

1.314 (1.231–1.421)

0.729 (0.644–0.826)

0.557 (0.500–0.646)

BMI

<25 (n = 58)

1.307 (1.221–1.424)

0.084

0.740 (0.651–0.813)

0.487

0.571 (0.506–0.630)

0.287

25–30 (n = 58)

1.314 (1.244–1.476)

0.762 (0.655–0.906)

0.582 (0.491–0.679)

>30 (n = 26)

1.267 (1.203–1.378)

0.762 (0.647–0.897)

0.597 (0.545–0.665)

Tumor location

Proximal colon (n = 49)

1.268 (1.223–1.444)

0.184

0.753 (0.655–0.878)

0.241

0.573 (0.490–0.684)

0.964

Distal colon (n = 27)

1.278 (1.073–1.371)

0.688 (0.641–0.797)

0.562 (0.509–0.657)

Rectum (n = 68)

1.316 (1.248–1.431)

0.766 (0.669–0.896)

0.582 (0.506–0.661)

TNM Stage

Stage I (n = 25)

1.392 (1.251–1.558)

0.038

0.780 (0.691–0.960)

0.282

0.592 (0.517–0.669)

0.202

Stage II (n = 54)

1.332 (1.235–1.421)

0.733 (0.648–0.852)

0.525 (0.495–0.644)

Stage III (n = 44)

1.303 (1.231–1.445)

0.753 (0.658–0.876)

0.585 (0.523–0.663)

Stage IV (n = 19)

1.251 (1.073–1.311)

0.768 (0.612–0.957)

0.627 (0.501–0.780)

Depth of invasion

T1 (n = 4)

1.318 (1.208–1.553)

0.008

0.837 (0.666–1.085)

0.084

0.590 (0.549–0.755)

0.653

T2 (n = 28)

1.362 (1.274–1.547)

0.791 (0.670–0.956)

0.593 (0.509–0.677)

T3 (n = 100)

1.303 (1.232–1.411)

0.746 (0.650–0.876)

0.563 (0.498–0.658)

T4 (n = 11)

1.087 (0.962–1.243)

0.636 (0.598–0.869)

0.552 (0.517–0.763)

Nodal metastasis

N0 (n = 83)

1.327 (1.234–1.443)

0.021

0.747 (0.660–0.877)

0.380

0.558 (0.497–0.658)

0.010

N1 (n =  = 35)

1.316 (1.252–1.456)

0.747 (0.644–0.869)

0.562 (0.493–0.621)

N2 (n = 24)

1.239 (1.160–1.303)

0.789 (0.646–0.966)

0.647 (0.589–0.732)

Distant metastasis

M0 (n = 124)

1.317 (1.233–1.444)

0.019

0.748 (0.661–0.876)

0.922

0.576 (0.501–0.652)

0.176

M1 (n = 19)

1.251 (1.073–1.311)

0.768 (0.612–0.957)

0.627 (0.501–0.780)

WHO Grade 1–3

Grade 1 (n = 19)

1.404 (1.255–1.563)

0.024

0.726 (0.660–0.869)

0.897

0.540 (0.493–0.594)

0.196

Grade 2 (n = 105)

1.302 (1.234–1.404)

0.749 (0.661–0.880)

0.580 (0.502–0.660)

Grade 3 (n = 19)

1.243 (1.047–1.419)

0.732 (0.598–0.948)

0.622 (0.495–0.761)

Necrosis

9% or less (n = 71)

1.316 (1.247–1.428)

0.179

0.739 (0.654–0.855)

0.362

0.558 (0.485–0.634)

0.041

10% or more (n = 72)

1.294 (1.219–1.429)

0.771 (0.650–0.885)

0.589 (0.517–0.688)

Modified Glasgow Prognostic score (mGPS)

0 (n = 113)

1.316 (1.242–1.447)

0.001

0.753 (0.674–0.882)

0.108

0.574 (0.496–0.658)

0.154

1–2 (n = 31)

1.216 (1.047–1.369)

0.726 (0.607–0.850)

0588 (0.524–0.763)

Cholesterol-lowering medication

No (n = 98)

1.313 (1.230–1.452)

0.171

0.777 (0.679–0.902)

0.001

0.592 (0.515–0.684)

0.015

Yes (n = 46)

1.285 (1.231–1.367)

0.711 (0.602–0.762)

0.538 (0.495–0.592)

  1. Abbreviations: IQR: interquartile range; BMI: body mass index. P values are for Mann-Whitney or Kruskal-Wallis test.
Back to article page